Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Continues Safety Policy Limiting Teenage Use Of Tamiflu

This article was originally published in PharmAsia News

Executive Summary

The Drug Safety Committee at the Pharmaceutical and Food Sanitization Council of Japan's Ministry of Health, Labor and Welfare June 16 decided to continue its current safety measure of limiting Tamiflu (oseltamivir) use in minors over 10 years of age. The committee's decision was based on two working group's scientific and clinical findings, which noted that although there was no statistical significance between Tamiflu users and non-users in the age group, the users had 1.54 times higher risk of developing abnormal behavior. The groups also stated that the research couldn't establish a casual relationship between taking Tamiflu and abnormal behavior. The safety policy was initiated in March 2007 when the Ministry received reports of teenagers showing abnormal behaviors after taking Tamiflu. (Click here for more - Japanese Language

You may also be interested in...



Komipharm In Spotlight As It Files For Emergency Trials Against Coronavirus

Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.

QUOTED. 27 February 2020. Michael Gibson.

Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.

Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.

UsernamePublicRestriction

Register

SC071924

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel